177 related articles for article (PubMed ID: 11181432)
1. Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment.
Cottet-Maire F; Avdonin PV; Roulet E; Buetler TM; Mermod N; Ruegg UT
Br J Pharmacol; 2001 Feb; 132(4):909-17. PubMed ID: 11181432
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin A.
Lo Russo A; Passaquin AC; Rüegg UT
Br J Pharmacol; 1997 May; 121(2):248-52. PubMed ID: 9154334
[TBL] [Abstract][Full Text] [Related]
3. Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity.
Lo Russo A; Passaquin AC; André P; Skutella M; Rüegg UT
Br J Pharmacol; 1996 Jun; 118(4):885-92. PubMed ID: 8799558
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin type 1A receptor up-regulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide.
Krauskopf A; Lhote P; Mutter M; Dufour JF; Ruegg UT; Buetler TM
J Biol Chem; 2003 Oct; 278(43):41685-90. PubMed ID: 12923165
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells.
Murasawa S; Matsubara H; Kizima K; Maruyama K; Mori Y; Inada M
Hypertension; 1995 Oct; 26(4):665-9. PubMed ID: 7558228
[TBL] [Abstract][Full Text] [Related]
7. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells.
Kusano E; Tian S; Umino T; Tetsuka T; Ando Y; Asano Y
J Hypertens; 1997 Jun; 15(6):627-32. PubMed ID: 9218182
[TBL] [Abstract][Full Text] [Related]
8. V1a vasopressin receptor expression is modulated during myogenic differentiation.
Alvisi M; De Arcangelis V; Ciccone L; Palombi V; Alessandrini M; Nemoz G; Molinaro M; Adamo S; Naro F
Differentiation; 2008 Apr; 76(4):371-80. PubMed ID: 18021262
[TBL] [Abstract][Full Text] [Related]
9. Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation.
Park F; Mattson DL; Skelton MM; Cowley AW
Am J Physiol; 1997 Jul; 273(1 Pt 2):R243-51. PubMed ID: 9249556
[TBL] [Abstract][Full Text] [Related]
10. Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin. Insights into molecular coevolution of V1a type receptors and their ligands.
Acharjee S; Do-Rego JL; Oh DY; Ahn RS; Choe H; Vaudry H; Kim K; Seong JY; Kwon HB
J Biol Chem; 2004 Dec; 279(52):54445-53. PubMed ID: 15475353
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of V(1) receptors in renal resistance vessels of rats developing genetic hypertension.
Vågnes O; Feng JJ; Iversen BM; Arendshorst WJ
Am J Physiol Renal Physiol; 2000 Jun; 278(6):F940-8. PubMed ID: 10836981
[TBL] [Abstract][Full Text] [Related]
12. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin V
Zhang L; Wang X; Cao H; Chen Y; Chen X; Zhao X; Xu F; Wang Y; Woo AY; Zhu W
Eur J Pharmacol; 2016 Dec; 792():15-25. PubMed ID: 27773680
[TBL] [Abstract][Full Text] [Related]
14. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats.
Ostrowski NL; Young WS; Knepper MA; Lolait SJ
Endocrinology; 1993 Oct; 133(4):1849-59. PubMed ID: 8404628
[TBL] [Abstract][Full Text] [Related]
15. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V
Taveau C; Chollet C; Bichet DG; Velho G; Guillon G; Corbani M; Roussel R; Bankir L; Melander O; Bouby N
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E127-E135. PubMed ID: 27998960
[TBL] [Abstract][Full Text] [Related]
16. Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line.
Yazawa H; Hirasawa A; Horie K; Saita Y; Iida E; Honda K; Tsujimoto G
Br J Pharmacol; 1996 Mar; 117(5):799-804. PubMed ID: 8851493
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid regulation of vasopressin V1a receptors in rat forebrain.
Watters JJ; Wilkinson CW; Dorsa DM
Brain Res Mol Brain Res; 1996 Jun; 38(2):276-84. PubMed ID: 8793116
[TBL] [Abstract][Full Text] [Related]
18. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor.
Birumachi J; Hiroyama M; Fujiwara Y; Aoyagi T; Sanbe A; Tanoue A
Eur J Pharmacol; 2007 Jul; 566(1-3):226-30. PubMed ID: 17449028
[TBL] [Abstract][Full Text] [Related]
19. Low pH stimulates vasopressin V2 receptor promoter activity and enhances downregulation induced by V1a receptor stimulation.
Memetimin H; Izumi Y; Nakayama Y; Kohda Y; Inoue H; Nonoguchi H; Tomita K
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F620-8. PubMed ID: 19587140
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin A potentiates receptor-activated [Ca2+]c increase.
Lo Russo A; Passaquin AC; Cox C; Rüegg UT
J Recept Signal Transduct Res; 1997; 17(1-3):149-61. PubMed ID: 9029487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
